Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW)

Reviva Pharmaceuticals Holdings, Inc. RVPHW

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 0.1901

-2.51 %

$ 40.2 M

Market Cap

None

P/E

1. INTRINSIC VALUE

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.[ Read More ]

The intrinsic value of one RVPHW stock under the base case scenario is HIDDEN Compared to the current market price of 0.19 USD, Reviva Pharmaceuticals Holdings, Inc. is HIDDEN

RVPHW Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart RVPHW

FINANCIALS

Annual
Quarterly

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-24.3 M OPERATING INCOME

Growth Rates

1Year -140.55%

3Years -301.03%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-24.3 M NET INCOME

Growth Rates

1Year -185.61%

3Years -206.32%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-19 M OPERATING CASH FLOW

Growth Rates

1Year -77.73%

3Years -342.76%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0 INVESTING CASH FLOW

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

7.79 M FINANCING CASH FLOW

Growth Rates

1Year -75.34%

3Years 327.13%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-10.7 M OPERATING INCOME

Growth Rates

1Year -140.55%

3Years -301.03%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-12.4 M NET INCOME

Growth Rates

1Year -185.61%

3Years -206.32%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-5.32 M OPERATING CASH FLOW

Growth Rates

1Year -77.73%

3Years -342.76%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0 INVESTING CASH FLOW

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

5.21 M FINANCING CASH FLOW

Growth Rates

1Year -75.34%

3Years 327.13%

5Years 0.00%

7Years 0.00%

10Years 0.00%

Balance Sheet Decomposition Reviva Pharmaceuticals Holdings, Inc.

18.9 M ASSETS
6.61 M LIABILITIES

Current Assets	18.9 M
Cash & Short-Term Investments	18.5 M
Receivables	0
Other Current Assets	404 K
Non-Current Assets	0
Long-Term Investments	0
PP&E	0
Other Non-Current Assets	0

Current Liabilities	6.04 M
Accounts Payable	3.52 M
Short-Term Debt	0
Other Current Liabilities	2.52 M
Non-Current Liabilities	567 K
Long-Term Debt	0
Other Non-Current Liabilities	567 K

EFFICIENCY

Earnings Waterfall Reviva Pharmaceuticals Holdings, Inc.

Revenue	0
Cost Of Revenue	0
Gross Profit	0
Operating Expenses	24.3 M
Operating Income	-24.3 M
Other Expenses	32.7 K
Net Income	-24.3 M

RATIOS

0.00% GROSS MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0.00% OPERATING MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0.00% NET MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-197.62% ROE

Averages

1Year -197.62%

3Years -92.75%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-128.62% ROA

Averages

1Year -128.62%

3Years -66.31%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-197.52% ROIC

Averages

1Year -197.52%

3Years -88.52%

5Years 0.00%

7Years 0.00%

10Years 0.00%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Reviva Pharmaceuticals Holdings, Inc.

Net Income	-24.3 M
Depreciation & Amortization	195 K
Capital Expenditures	0
Stock-Based Compensation	177 K
Change in Working Capital	5.01 M
Others	2.19 M
Free Cash Flow	-19 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Reviva Pharmaceuticals Holdings, Inc.

RVPHW has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

0.949 USD

RVPH

Overvalued 15.65%

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.

2.43 USD

ATNFW

Undervalued 29918.00%

6. Ownership

Insider Ownership Reviva Pharmaceuticals Holdings, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
2 years ago Nov 18, 2022	Bought 14.1 K USD	Patel Purav Director	+ 3000	4.69 USD
2 years ago Sep 08, 2022	Bought 87 USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 869565	0.0001 USD
2 years ago Sep 08, 2022	Bought 2.09 M USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 869565	2.4 USD
2 years ago Sep 08, 2022	Bought 51.4 USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 513834	0.0001 USD
2 years ago Sep 08, 2022	Bought 1.23 M USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 513834	2.4 USD
3 years ago Jun 01, 2021	Bought 3.84 M USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 931000	4.125 USD
3 years ago Jun 01, 2021	Bought 3.49 M USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 931000	3.75 USD
3 years ago Jun 01, 2021	Bought 1.5 M USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 399000	3.75 USD
3 years ago Jun 01, 2021	Bought 1.65 M USD	VEDANTA PARTNERS, LLC 10 percent owner	+ 399000	4.125 USD
3 years ago Dec 08, 2020	Sell 3.99 M USD	GLAZER CAPITAL, LLC 10 percent owner	- 367000	10.88 USD
3 years ago Dec 07, 2020	Sell 576 K USD	Hudson Bay Capital Management LP 10 percent owner	- 50000	11.51 USD
3 years ago Dec 02, 2020	Sell 2.87 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 261	11 USD
3 years ago Nov 27, 2020	Sell 65.1 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 5969	10.9 USD
3 years ago Dec 01, 2020	Sell 59 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 5362	11 USD
3 years ago Nov 23, 2020	Sell 257 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 23611	10.9 USD
3 years ago Nov 24, 2020	Sell 77.4 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 7103	10.9 USD
4 years ago Nov 16, 2020	Sell 3.32 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 305	10.9 USD
4 years ago Nov 17, 2020	Sell 1.38 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 127	10.9 USD
4 years ago Nov 18, 2020	Sell 9.77 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 896	10.9 USD
4 years ago Nov 11, 2020	Sell 54.5 USD	GLAZER CAPITAL, LLC 10 percent owner	- 5	10.9 USD
4 years ago Nov 06, 2020	Sell 10.9 USD	GLAZER CAPITAL, LLC 10 percent owner	- 1	10.9 USD
4 years ago Nov 02, 2020	Sell 11.5 USD	GLAZER CAPITAL, LLC 10 percent owner	- 1	11.5 USD
4 years ago Nov 03, 2020	Sell 625 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 57616	10.85 USD
4 years ago Mar 20, 2020	Bought 104 K USD	Hudson Bay Capital Management LP 10 percent owner	+ 10000	10.37 USD
4 years ago Nov 02, 2020	Sell 544 K USD	Hudson Bay Capital Management LP 10 percent owner	- 50000	10.87 USD
4 years ago Sep 29, 2020	Sell 23 USD	GLAZER CAPITAL, LLC 10 percent owner	- 2	11.5 USD
4 years ago Sep 17, 2020	Sell 10.8 K USD	GLAZER CAPITAL, LLC 10 percent owner	- 1000	10.8 USD
4 years ago Sep 14, 2020	Sell 10.8 USD	GLAZER CAPITAL, LLC 10 percent owner	- 1	10.8 USD
4 years ago May 08, 2020	Sell 542 K USD	MIZUHO SECURITIES USA LLC 10 percent owner	- 51000	10.62 USD
6 years ago Aug 30, 2018	Bought 330 K USD	Tenzing LLC 10 percent owner	+ 33000	10 USD
6 years ago Aug 30, 2018	Bought 330 K USD	Nayar Rahul Chief Executive Officer	+ 33000	10 USD
6 years ago Aug 30, 2018	Bought 330 K USD	SAXENA PARAG Chairman of the Board	+ 33000	10 USD
6 years ago Aug 23, 2018	Bought 3.1 M USD	Nayar Rahul Chief Executive Officer	+ 310000	10 USD
6 years ago Aug 23, 2018	Bought 3.1 M USD	SAXENA PARAG Chairman of the Board	+ 310000	10 USD
6 years ago Aug 23, 2018	Bought 3.1 M USD	Tenzing LLC 10 percent owner	+ 310000	10 USD

7. News

8. Profile Summary

Reviva Pharmaceuticals Holdings, Inc. RVPHW

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 40.2 M

Dividend Yield 0.00%

Description Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

Contact 19925 Stevens Creek Boulevard, Cupertino, 95014 https://www.revivapharma.com

IPO Date None

Employees 15

Officers Dr. Laxminarayan Bhat Ph.D. Founder, Chief Executive Officer, President & Director Mr. Narayan Prabhu Chief Financial Officer

Price Chart RVPHW

Reviva Pharmaceuticals Holdings, Inc. RVPHW

Premium Plan

Unlimited Plan